Evidence map›Paper›PMID 32655837›Full record

ArticleOncotarget2020

Inhibition of the RUNX1-CBFβ transcription factor complex compromises mammary epithelial cell identity: a phenotype potentially stabilized by mitotic gene bookmarking.

Joshua T Rose, Eliana Moskovitz, Joseph R Boyd, Jonathan A Gordon, Nicole A Bouffard, Andrew J Fritz, Anuradha Illendula, John H Bushweller, Jane B Lian, Janet L Stein and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Joshua T RoseDepartment of Biochemistry and University of Vermont Cancer Center, Robert Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Eliana MoskovitzDepartment of Biochemistry and University of Vermont Cancer Center, Robert Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Joseph R BoydDepartment of Biochemistry and University of Vermont Cancer Center, Robert Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Jonathan A GordonDepartment of Biochemistry and University of Vermont Cancer Center, Robert Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Nicole A BouffardMicroscopy Imaging Center at the Robert Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Andrew J FritzDepartment of Biochemistry and University of Vermont Cancer Center, Robert Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Anuradha IllendulaDepartment of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA.
John H BushwellerDepartment of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA.
Jane B LianDepartment of Biochemistry and University of Vermont Cancer Center, Robert Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Janet L SteinDepartment of Biochemistry and University of Vermont Cancer Center, Robert Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Sayyed K ZaidiDepartment of Biochemistry and University of Vermont Cancer Center, Robert Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Gary S SteinDepartment of Biochemistry and University of Vermont Cancer Center, Robert Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
University of Vermont · USUniversity of Virginia · US

Funding

Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted InterventionsU54GM115516 · NIGMS · MAINEHEALTH · PI Robert A Koza · 2017 to 2026
$51.6M
SUBNUCLEAR TARGETING OF TRANSCRIPTION FACTORSP01CA082834 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STEIN, GARY S. · 2001 to 2015
$18.4M
Vermont Breast Cancer Molecular Characterization LaboratoryU01CA196383 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SPRAGUE, BRIAN L, STEIN, JANET L · 2015 to 2020
$5.4M
Targeted Small Molecule Inhibitors for Inv(16) LeukemiaR01CA234478 · NCI · UNIVERSITY OF VIRGINIA · PI BUSHWELLER, JOHN HACKETT, CASTILLA, LUCIO H. · 2019 to 2023
$3.4M
Chromatin Organization Regulates OsteogenesisR01DE029311 · NIDCR · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI LIAN, JANE B., STEIN, GARY S. · 2020 to 2024
$2.5M
Nikon A1R-ER Confocal Microscope for the Microscopy Imaging CenterS10OD025030 · OD · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI TAATJES, DOUGLAS J. · 2018 to 2018
$557k
INVERTED LASER-SCANNING CONFOCAL MICROSCOPE: LUNG RESEARCHS10RR019246 · NCRR · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI TAATJES, DOUGLAS J. · 2004 to 2004
$473k
Supplement to AWD32581 - Fritz fellowship F32CA220935F32CA220935 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI FRITZ, ANDREW J · 2018 to 2021
$216k
NCI NIH HHS F32 CA220935NCI NIH HHS P01 CA082834NCI NIH HHS R01 CA234478NCI NIH HHS U01 CA196383NCRR NIH HHS S10 RR019246NIDCR NIH HHS R01 DE029311NIGMS NIH HHS U54 GM115516NIH HHS S10 OD025030
6 · The paper itself

Abstract

RUNX1 has recently been shown to play an important role in determination of mammary epithelial cell identity. However, mechanisms by which loss of the RUNX1 transcription factor in mammary epithelial cells leads to epithelial-to-mesenchymal transition (EMT) are not known. Here, we report that interaction between RUNX1 and its heterodimeric partner CBFβ is essential for sustaining mammary epithelial cell identity. Disruption of RUNX1-CBFβ interaction, DNA binding, and association with mitotic chromosomes alters cell morphology, global protein synthesis, and phenotype-related gene expression. During interphase, RUNX1 is organized as punctate, predominantly nuclear, foci that are dynamically redistributed during mitosis, with a subset localized to mitotic chromosomes. Genome-wide RUNX1 occupancy profiles for asynchronous, mitotically enriched, and early G1 breast epithelial cells reveal RUNX1 associates with RNA Pol II-transcribed protein coding and long non-coding RNA genes and RNA Pol I-transcribed ribosomal genes critical for mammary epithelial proliferation, growth, and phenotype maintenance. A subset of these genes remains occupied by the protein during the mitosis to G1 transition. Together, these findings establish that the RUNX1-CBFβ complex is required for maintenance of the normal mammary epithelial phenotype and its disruption leads to EMT. Importantly, our results suggest, for the first time, that RUNX1 mitotic bookmarking of a subset of epithelial-related genes may be an important epigenetic mechanism that contributes to stabilization of the mammary epithelial cell identity.

Indexed as

CBFβepithelial phenotypemammary epithelial phenotypemitotic gene bookmarkingRUNX1

Identifiers

PMID32655837
PMCPMC7335667
OpenAlexW3039574079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.